# Vanita R. Aroda

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vanita-r-aroda/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,193 |
| Field | Diabetes Treatment and Management |
| h-index | 70 |
| i10-index | 181 |
| Last Known Institution | Brigham and Women's Hospital |
| OpenAlex ID | https://openalex.org/A5005405894 |
| ORCID iD | https://orcid.org/0000-0002-7706-4585 |
| Works | 387 |

## Researcher papers

- [2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>](https://scholariq.org/papers/2-classification-and-diagnosis-of-diabetes-i-standards-of-care-in-diabetes-2023/)
- [Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)](https://scholariq.org/papers/management-of-hyperglycemia-in-type-2-diabetes-2022-a-consensus-report-by-the/)
- [Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)](https://scholariq.org/papers/management-of-hyperglycaemia-in-type-2-diabetes-2022-a-consensus-report-by-the/)
- [Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial](https://scholariq.org/papers/semaglutide-versus-dulaglutide-once-weekly-in-patients-with-type-2-diabetes/)
- [Vitamin D Supplementation and Prevention of Type 2 Diabetes](https://scholariq.org/papers/vitamin-d-supplementation-and-prevention-of-type-2-diabetes/)
- [PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes](https://scholariq.org/papers/pioneer-1-randomized-clinical-trial-of-the-efficacy-and-safety-of-oral/)
- [Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial](https://scholariq.org/papers/efficacy-and-safety-of-once-weekly-semaglutide-versus-once-daily-insulin/)
- [Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/oral-semaglutide-50-mg-taken-once-per-day-in-adults-with-overweight-or-obesity/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)

## Researcher university

- [Brigham and Women's Hospital](https://scholariq.org/institutions/brigham-and-women-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.